mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
- PMID: 21933437
- PMCID: PMC3193807
- DOI: 10.1186/1755-8794-4-66
mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
Abstract
Background: Conventional high-grade osteosarcoma is a primary malignant bone tumor, which is most prevalent in adolescence. Survival rates of osteosarcoma patients have not improved significantly in the last 25 years. Aiming to increase this survival rate, a variety of model systems are used to study osteosarcomagenesis and to test new therapeutic agents. Such model systems are typically generated from an osteosarcoma primary tumor, but undergo many changes due to culturing or interactions with a different host species, which may result in differences in gene expression between primary tumor cells, and tumor cells from the model system. We aimed to investigate whether gene expression profiles of osteosarcoma cell lines and xenografts are still comparable to those of the primary tumor.
Methods: We performed genome-wide mRNA expression profiling on osteosarcoma biopsies (n = 76), cell lines (n = 13), and xenografts (n = 18). Osteosarcoma can be subdivided into several histological subtypes, of which osteoblastic, chondroblastic, and fibroblastic osteosarcoma are the most frequent ones. Using nearest shrunken centroids classification, we generated an expression signature that can predict the histological subtype of osteosarcoma biopsies.
Results: The expression signature, which consisted of 24 probes encoding for 22 genes, predicted the histological subtype of osteosarcoma biopsies with a misclassification error of 15%. Histological subtypes of the two osteosarcoma model systems, i.e. osteosarcoma cell lines and xenografts, were predicted with similar misclassification error rates (15% and 11%, respectively).
Conclusions: Based on the preservation of mRNA expression profiles that are characteristic for the histological subtype we propose that these model systems are representative for the primary tumor from which they are derived.
Figures



Similar articles
-
Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.Bone. 2011 Sep;49(3):356-67. doi: 10.1016/j.bone.2011.05.008. Epub 2011 May 15. Bone. 2011. PMID: 21621658 Free PMC article.
-
Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.Int Orthop. 2011 Mar;35(3):401-11. doi: 10.1007/s00264-010-0996-6. Epub 2010 Mar 26. Int Orthop. 2011. PMID: 20340016 Free PMC article.
-
Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.Eur J Cancer. 2002 Jun;38(9):1218-25. doi: 10.1016/s0959-8049(02)00037-0. Eur J Cancer. 2002. PMID: 12044509 Clinical Trial.
-
Molecular classification of osteosarcoma.Cancer Treat Res. 2009;152:459-65. doi: 10.1007/978-1-4419-0284-9_26. Cancer Treat Res. 2009. PMID: 20213408 Review.
-
Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor.Int J Cancer. 2013 Dec 1;133(11):2512-21. doi: 10.1002/ijc.28124. Epub 2013 Mar 16. Int J Cancer. 2013. PMID: 23436697 Review.
Cited by
-
Multitype Network-Guided Target Controllability in Phenotypically Characterized Osteosarcoma: Role of Tumor Microenvironment.Front Immunol. 2017 Jul 31;8:918. doi: 10.3389/fimmu.2017.00918. eCollection 2017. Front Immunol. 2017. PMID: 28824643 Free PMC article.
-
The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review.Oncogene. 2023 Jan;42(4):259-277. doi: 10.1038/s41388-022-02529-x. Epub 2022 Nov 25. Oncogene. 2023. PMID: 36434179 Free PMC article.
-
Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.Br J Cancer. 2013 Oct 15;109(8):2228-36. doi: 10.1038/bjc.2013.549. Epub 2013 Sep 24. Br J Cancer. 2013. PMID: 24064976 Free PMC article.
-
Modulation of the osteosarcoma expression phenotype by microRNAs.PLoS One. 2012;7(10):e48086. doi: 10.1371/journal.pone.0048086. Epub 2012 Oct 25. PLoS One. 2012. PMID: 23133552 Free PMC article.
-
Immuno-Oncology Integrative Networks: Elucidating the Influences of Osteosarcoma Phenotypes.Cancer Inform. 2017 Jul 26;16:1176935117721691. doi: 10.1177/1176935117721691. eCollection 2017. Cancer Inform. 2017. PMID: 28804242 Free PMC article. Review.
References
-
- Cleton-Jansen AM, Buerger H, Hogendoom PCW. Central high-grade osteosarcoma of bone: Diagnostic and genetic considerations. Current Diagnostic Pathology. 2005;11:390–399. doi: 10.1016/j.cdip.2005.08.005. - DOI
-
- Raymond AK, Ayala AG, Knuutila S. In: World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F, editor. Lyon: IARC Press; 2002. Conventional osteosarcoma; pp. 264–270.
-
- Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PCW, Lankester AC, Gelderblom H. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer. 2010;54:216–221. - PubMed
-
- Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PCW, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AHM. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128. doi: 10.1093/jnci/djk015. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases